Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
 arrow  Full Text of this article Free
space
 arrow  Figures/Tables List
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Yang, Q.
space
  arrow  Parrish, R. G.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

POPULATION-BASED DATA

Hemochromatosis-Associated Mortality in the United States from 1979 to 1992: An Analysis of Multiple-Cause Mortality Data

right arrow Quanhe Yang, PhD; Sharon M. McDonnell, MD, MPH; Muin J. Khoury, MD, PhD; Joanne Cono, MD, ScM; and R. Gibson Parrish, MD

1 December 1998 | Volume 129 Issue 11 Part 2 | Pages 946-953

Background: Hemochromatosis, which can lead to serious chronic diseases resulting from iron overload, has an estimated prevalence of 50 to 80 cases per 10 000 persons. However, little population-based information is available on the impact of hemochromatosis on morbidity and mortality.

Objective: To evaluate trends over 14 years in deaths and medical conditions associated with hemochromatosis in the United States.

Design: We searched Multiple-Cause Mortality Files compiled by the National Center for Health Statistics for the years 1979 to 1992 for all records listing hemochromatosis. We used these data to calculate age-adjusted and age-specific mortality rates, identify medical conditions associated with a known diagnosis of hemochromatosis at death, and calculate proportionate mortality ratios for these medical conditions.

Results: The listing of hemochromatosis on death certificates increased 60% from 1979 to 1992. Decedents with hemochromatosis were 23, 13, and 5 times more likely to have liver neoplasms, liver disease, and cardiomyopathy, respectively, than were decedents without hemochromatosis. Conversely, decedents with liver neoplasms, liver disease, and cardiomyopathy were 26, 14, and 5 times more likely, respectively, to have hemochromatosis than were decedents without these conditions. Hemochromatosis was 82 times more likely in persons with the combination of liver neoplasms and diabetes and 43 times more likely in those with the combination of liver disease and diabetes than in those without these conditions.

Conclusions: Comparison of the reported prevalence of hemochromatosis among decedents with estimates of prevalence in the general U.S. population suggests that either the penetrance or the recognition of hemochromatosis, or both, is low. Nevertheless, substantial mortality resulting from liver disease, liver neoplasms, cardiomyopathy, and a combination of liver disease and diabetes in patients with hemochromatosis argues for the improved diagnosis and treatment of hemochromatosis in persons with these conditions.

Author and Article Information
space

From the Centers for Disease Control and Prevention and Egleston Children's Hospital at Emory University, Atlanta, Georgia.
Previously presented in part at Prevention 97 in Atlanta, Georgia, 20-23 March 1997.
Acknowledgments: The authors thank Drs. J. David Erickson, David Mannino, Kyle Steenland, and Mary E. Cogswell for helpful comments and technical assistance.
Requests for Reprints: Sharon M. McDonnell, MD, MPH, Division of International Health, Centers for Disease Control and Prevention, Mailstop C-08, 1600 Clifton Road, Atlanta, GA 30333; e-mail, sem0{at}cdc.gov.
Current Author Addresses: Dr. Yang: Division of Birth Defects and Developmental Disabilities, National Center for Environmental Health, Centers for Disease Control and Prevention, Mailstop F-45, 4770 Buford Highway, Atlanta, GA 30341.
Dr. McDonnell: Division of International Health, Centers for Disease Control and Prevention, Mailstop C-08, 1600 Clifton Road, Atlanta, GA 30333.
Dr. Khoury: Office of Genetics and Disease Prevention, Centers for Disease Control and Prevention, Mailstop K-28, 4770 Buford Highway, Atlanta, GA 30341.
Dr. Cono: Egleston Children's Hospital at Emory University, Department of General Pediatrics, 311 St. Paul Avenue, Atlanta, GA 30312.
Dr. Parrish: Division of Environmental Hazards and Health Effects, National Center for Environmental Health, Centers for Disease Control and Prevention, Mailstop F-47, 4770 Buford Highway, Atlanta, GA 30341.
Note: This article is one of a series of articles comprising an Annals of Internal Medicine supplement entitled "Iron Overload, Public Health, and Genetics." To view a complete list of the articles included in this supplement, please view its Table of Contents.




This article has been cited by other articles:


Home page
ANN INTERN MEDHome page
E. P. Whitlock, B. A. Garlitz, E. L. Harris, T. L. Beil, and P. R. Smith
Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force.
Ann Intern Med, August 1, 2006; 145(3): 209 - 223.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
B. Schmitt, R. M. Golub, and R. Green
Screening Primary Care Patients for Hereditary Hemochromatosis with Transferrin Saturation and Serum Ferritin Level: Systematic Review for the American College of Physicians
Ann Intern Med, October 4, 2005; 143(7): 522 - 536.
[Abstract] [Full Text] [PDF]


Home page
Ann Fam MedHome page
A. G. Mainous III, J. M. Gill, and P. J. Carek
Elevated Serum Transferrin Saturation and Mortality
Ann. Fam. Med, March 1, 2004; 2(2): 133 - 138.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
S. Dubois and K. V. Kowdley
The Importance of Screening for Hemochromatosis
Arch Intern Med, November 10, 2003; 163(20): 2424 - 2426.
[Full Text] [PDF]


Home page
Hum Exp ToxicolHome page
M. Galleano, A. Lemberg, and S. Puntarulo
Does hepatomegaly alter iron-dependent oxidative effects in human plasma?
Human and Experimental Toxicology, July 1, 2003; 22(7): 401 - 405.
[Abstract] [PDF]


Home page
GutHome page
S D Ryder
Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults
Gut, May 1, 2003; 52(90003): iii1 - 8.
[Full Text] [PDF]


Home page
NEJMHome page
M. J. Khoury, L. L. McCabe, and E. R.B. McCabe
Population Screening in the Age of Genomic Medicine
N. Engl. J. Med., January 2, 2003; 348(1): 50 - 58.
[Full Text] [PDF]


Home page
ASH Education BookHome page
E. Beutler, A. V. Hoffbrand, and J. D. Cook
Iron Deficiency and Overload
Hematology, January 1, 2003; 2003(1): 40 - 61.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
C. T Sempos
Do body iron stores increase the risk of developing coronary heart disease?
Am. J. Clinical Nutrition, September 1, 2002; 76(3): 501 - 503.
[Full Text] [PDF]


Home page
Am J EpidemiolHome page
E. H. Hanson, G. Imperatore, and W. Burke
HFE Gene and Hereditary Hemochromatosis: A HuGE Review
Am. J. Epidemiol., August 1, 2001; 154(3): 193 - 206.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
M Bhavnani, D Lloyd, A Bhattacharyya, J Marples, P Elton, and M Worwood
Screening for genetic haemochromatosis in blood samples with raised alanine aminotransferase
Gut, May 1, 2000; 46(5): 707 - 710.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
G. Willis, I. W Fellows, and J. Z Wimperis
Deaths attributed to haemochromatosis are rare in Britain
BMJ, April 22, 2000; 320(7242): 1146 - 1146.
[Full Text]


Home page
GutHome page
G Willis, J Z Wimperis, R Lonsdale, I W Fellows, M A Watson, L M Skipper, and B A Jennings
Incidence of liver disease in people with HFE mutations
Gut, March 1, 2000; 46(3): 401 - 404.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
A. BESARAB, S. FRINAK, and J. YEE
An Indistinct Balance: The Safety and Efficacy of Parenteral IronTherapy
J. Am. Soc. Nephrol., September 1, 1999; 10(9): 2029 - 2043.
[Full Text]


Home page
BMJHome page
J. E Haddow and L. A Bradley
Hereditary haemochromatosis: to screen or not
BMJ, August 28, 1999; 319(7209): 531 - 532.
[Full Text]


Home page
ANN INTERN MEDHome page
L. W. Powell, D. K. George, S. M. McDonnell, and K. V. Kowdley
Diagnosis of Hemochromatosis
Ann Intern Med, December 1, 1998; 129(11_Part_2): 925 - 931.
[Abstract] [Full Text]


Home page
ANN INTERN MEDHome page
M. E. Cogswell, S. M. McDonnell, M. J. Khoury, A. L. Franks, W. Burke, and G. Brittenham
Iron Overload, Public Health, and Genetics: Evaluating the Evidence for Hemochromatosis Screening
Ann Intern Med, December 1, 1998; 129(11_Part_2): 971 - 979.
[Abstract] [Full Text]


Home page
ANN INTERN MEDHome page
S. F. Wetterhall, M. E. Cogswell, and K. V. Kowdley
Public Health Surveillance for Hereditary Hemochromatosis
Ann Intern Med, December 1, 1998; 129(11_Part_2): 980 - 986.
[Abstract] [Full Text]


Home page
ANN INTERN MEDHome page
S. M. McDonnell, D. L. Witte, M. E. Cogswell, and R. McIntyre
Strategies To Increase Detection of Hemochromatosis
Ann Intern Med, December 1, 1998; 129(11_Part_2): 987 - 992.
[Abstract] [Full Text]




 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online 

Copyright © 1998 by the American College of Physicians.